search for




 

Early Experiences of a Minimal Invasive Intra-Prostatic Implant, Prostatic Urethral Lift for Benign Prostatic Hyperplasia Treatment in Korea
Urogenit Tract Infect 2019 Dec;14(3):80-6
Published online December 31, 2019;  https://doi.org/10.14777/uti.2019.14.3.80
Copyright © 2019 Korean Association of Urogenital Tract Infection and Inflammation.

Jonghyup Yang, Dongho Shin, Jaewoo Sung, Shinjay Cho, Sungmin Kang, Hyun Cheol Jeong1, Sae Woong Choi2, Woong Jin Bae, Sae Woong Kim

Department of Urology, The Catholic University of Korea, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, 1Department of Urology, Kangdong Sacred Heart Hospital, Seoul, 2Department of Urology, The Catholic University of Korea, Yeouido St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea
Correspondence to: Sae Woong Kim
https://orcid.org/0000-0002-9127-9400
Department of Urology, The Catholic University of Korea, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, 222 Banpodaero, Seocho-gu, Seoul 06591, Korea
Tel: +82-2-2258-1401, Fax: +82-2-2258-1536
E-mail: ksw1227@catholic.ac.kr
Received May 30, 2019; Revised September 4, 2019; Accepted October 9, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Purpose: As a minimal invasive device for benign prostatic hyperplasia (BPH) treatment, prostatic urethral lift (PUL) is widely accepted worldwide but not widely used in Korea. We investigated the one-year results of for patients with BPH in Korea.
Materials and Methods: From April 2017 to June 2018, 42 patients with BPH were treated with PUL under local anesthesia with sedation. International Prostate Symptom Score (IPSS) and maximum urinary flow rate and post-void residual (PVR) were evaluated preoperatively and 1, 3, 6, and 12 months later.
Results: Mean age was 69.57±8.58 years old, and mean prostatic volume was 37.17±12.19 cc. Preoperative total IPSS and quality of life (QOL) were 19.94±7.81 and 3.69±1.30, respectively. Total IPSS improved to 11.26±7.22 (p<0.001), and QOL was 2.42±1.43 (p=0.01) after one month. Patients showed no evidence of inflammation related to the implants. IPSS and QOL were somewhat worse after 3 months but were better than baseline at 6 and 12 months. Preoperative maximum flow rate (Qmax) was 9.71±5.45 ml/sec, and one month after surgery, it had improved to 12.63±7.33 (p=0.01); it remained good at 3, 6, and 12 months (12.63±7.38, 12.45±7.39, 14.73±9.67). PVR was not significant at any points postoperative (80.61±67.91 to 43.95±8.19, p=0.119). No patient reported retrograde ejaculation, erectile dysfunction or urinary tract infection.
Conclusions: We evaluated the one-year efficacy of PUL for BPH treatment in Korea, and found significant improvement of IPSS, QOL and Qmax. It is expected that not only the improvement of voiding symptom but also the preservation of sexual function with a low risk of adverse events.
Keywords : Prostatic hyperplasia; Lower urinary tract symptoms; Transurethral resection of prostate; Adrenergic alpha-antagonists


December 2019, 14 (3)

  • The official journal of

    The Korean Association of Urogenital Tract Infection and Inflammation

    The Korean Continence Society

    The Han-nam Urological Association

    The Korean Society of Geriatric Urological Care